Human epidermal growth factor receptor 2 overexpression is associated with high-grade tumors in upper tract urothelial carcinoma

Table 2 Univariate and multivariable logistic regression analysis for the clinicopathologic characteristics on human epidermal growth factor receptor 2 expression

Variable	Univariate HR (95%CI)	P value	Multivariate HR (95%CI)	P value
Age (per year)	1.01 (0.98-1.04)	0.62
Gender (female vs male)	1.12 (0.58-2.17)	0.74
Tumor location (ureter vs renal pelvis)	1.13 (0.60-2.13)	0.71
pT stage (T2 vs ≤ T1)	0.72 (0.30-1.74)	0.47
pT stage (≥ T3 vs ≤ T1)	0.77 (0.36-1.65)	0.5
Grade (high vs low)	3.56 (1.30-9.75)	0.013a	3.42 (1.22-9.60)	0.019a
Ki-67 (high vs low)	0.76 (0.34-1.70)	0.5
Lymph node metastasis (yes vs no)	1.17 (0.30-4.58)	0.82
Lymphovascular invasion (yes vs no)	1.56 (0.76-3.20)	0.23
Laterality (right vs left)	1.17 (0.60-2.28)	0.647
Molecular subtype (basal vs luminal)	0.62 (0.24-1.60)	0.32
Molecular subtype (double-positive vs luminal)	1.08 (0.30-3.94)	0.9
Molecular subtype (double-negative vs luminal)	0.90 (0.26-3.14)	0.87

^aP < 0.05.

HER2: Human epidermal growth factor receptor 2; HR: Hazard ratio.